Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: SMARCAL1 pathological phases and aberrant expression levels in pan-cancer. A . An examination of SMARCAL1 mRNA expression across 26 different tumor types in comparison to normal tissues. B . Utilizing data from both the TCGA and GTEx databases to ascertain the mRNA expression levels of SMARCAL1. C. CPTAC demonstrated the differences in SMARCAL1 total protein levels across ccRCC, HCC, LUSC, GBM, UCEC, and normal tissues. D . The expression of SMARCAL1 protein in COAD, breast duct carcinoma, PRAD, LUAD, and liver cholangiocarcinoma

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques: Expressing, Comparison

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: Sangerbox analysis of cancer prognosis capacity of SMARCAL1 on TCGA samples. A . Overall survival. B . Disease-specific survival. C . Disease-free interval. D . Progression-free interval

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques:

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: Enrichment analysis SMARCAL1-associated genes. A Protein–Protein Interaction network of the top 20 co-expressed genes of SMARCAL1 in the GEPIA database. B KEGG pathway analysis. C GO analysis of SMARCAL1

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques:

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: Analysis of SMARCAL1 with the correlation of heterogeneity, genomic instability, mutation profiles, and methylation levels. A – D . Lollipop picture of the correlation between SMARCAL1 expression and TMB, MSI, MATH, and purity

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques: Mutagenesis, Methylation, Expressing

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: Relevance analysis between two immune cell types and SMARCAL1. A Macrophage M2. B Regulatory T cells

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques:

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: Analysis of the relationship between antitumor immunity and SMARCAL1 A Using GBM, SKCM, and KIRC cohorts, Kaplan–Meier plots show how OS differs between SMARCAL1 high and low expression groups following ICB treatment. B Comparison of SMARCAL1’s predictive power for ICB therapy with that of standardized biomarkers. C Correlation between SMARCAL1 and CTL. D The effect of SMARCAL1 expression levels on overall survival in cancer patients is demonstrated using a Kaplan–Meier survival study. E – G . Kaplan–Meier survival analysis illustrating the effect of SMARCAL1 expression levels on overall survival in cancer patients undergoing anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapy, respectively

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques: Expressing, Comparison

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: An investigation into the responsiveness of SMARCAL1 to chemotherapeutic agents and its predictive value for drug sensitivity. A The left panel’s box plot illustrates the association between SMARCAL1 expression and chemotherapy response, whereas the ROC curve on the right, sourced from the online ROC plotter resource, indicates the predictive accuracy of SMARCAL1 levels for chemotherapy responsiveness. B The study reveals that SMARCAL1 expression correlates with the chemosensitivity to fludarabine and methylprednisolone

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques: Expressing

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: Expression of SMARCAL1 mRNA and protein in non-small cell lung cancer (NSCLC). A Relative expression of SMARCAL1 in Normal and LUAD tissues. B qRT-PCR examination of the relative expression of SMARCAL1 mRNA in normal and NSCLC cell lines. C The protein level of SMARCAL1, as determined by Western blot. D – E . Immunohistochemical analysis detected the presence of SMARCAL1 protein in both corresponding normal and lung adenocarcinoma (LUAD) samples. **** p < 0.001

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Immunohistochemical staining

Journal: Discover Oncology

Article Title: Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

doi: 10.1007/s12672-025-03980-4

Figure Lengend Snippet: Expression of SMARCAL1 mRNA and protein in LUAD, NSCLC. A SMARCAL1 expression levels were obtained from the GEO database for normal, LUAD, and NSCLC tissues. B The ROC curve of SMARCAL1 in three databases. C – E . GSEA enrichment analysis of SMARCAL1 in NSCLC based on GSE31547 , GSE40791 , and GSE19804

Article Snippet: After 20 min of 5% BSA blocking, sections were treated with primary antibodies. (Mouse monoclonal SMARCAL1 antibody, 1:200, Novus, USA) at 4°C overnight.

Techniques: Expressing

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Article Title: SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.

doi: 10.1038/s41379-021-00841-7

Figure Lengend Snippet: Fig. 2 Immunohistochemistry to detect SMARCAL1. IHC for SMARCAL1 was performed on U87 cell line variants, either SMARCAL1 wild-type (A) or SMARCAL1 knockout (B). C Example of giant cell GBM lacking SMARCAL1 protein expression in the cancer cells as revealed by IHC. For all panels, original magnification ×400.

Article Snippet: For SMARCAL1, slides were steamed in EDTA buffer (Cat# AM9849, Invitrogen, Carlsbad, CA) for 45 min, blocked twice (Cat# S2003 and X0909, Dako, Denmark), then were incubated for 2 h at room temperature in primary antibody against SMARCAL1 (1:100 dilution, Cat# HPA020337, Atlas Antibodies, Bromma, Sweden).

Techniques: Immunohistochemistry, Knock-Out, Expressing

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Article Title: SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.

doi: 10.1038/s41379-021-00841-7

Figure Lengend Snippet: Fig. 4 Association between overall survival in classic giant cell glio- blastomas and glioblastomas with giant cell features based on mole- cular features. Kaplan–Meier curves and log rank tests demonstrate that there is not significant difference in overall survival based on A ATRX status (p = 0.08) or B SMARCAL1 status (p = 0.09); however, C there was a significantly better overall survival in patients with ALT-positive tumors compared to patients with ALT-negative tumors (p < 0.03).

Article Snippet: For SMARCAL1, slides were steamed in EDTA buffer (Cat# AM9849, Invitrogen, Carlsbad, CA) for 45 min, blocked twice (Cat# S2003 and X0909, Dako, Denmark), then were incubated for 2 h at room temperature in primary antibody against SMARCAL1 (1:100 dilution, Cat# HPA020337, Atlas Antibodies, Bromma, Sweden).

Techniques:

Journal: PLoS ONE

Article Title: Altering mammalian transcription networking with ADAADi: An inhibitor of ATP-dependent chromatin remodeling

doi: 10.1371/journal.pone.0251354

Figure Lengend Snippet: (A). The transcript levels of BRG1 , SMARCAL1 , INO80 , HELLS , ZRANB3 , PICH , and SWR1 was measured using qPCR in HeLa cells after treatment with ADAADi. (B). The transcript levels of CHD1L , CHD1 , CHD7 , CHD3 , BRM , ATRX , BTAF1 , EP400 , and RAD54L was measured using qPCR in HeLa cells after treatment with ADAADi. (C). The transcript levels of SMARCAL1 and BRG1 in HeLa cells after ADAADi treatment were measured using qPCR. (D). Expression of BRG1 and SMARCAL1 in HeLa cells was monitored by western blot after 24 and 48 hr of treatment. (E). Quantitation of the western blot was done using Image J software and normalized with respect to β-actin. (F). The ATPase activity of SMARCAL1 was measured in untreated and ADAADi-treated HeLa cells. (E). The ATPase activity of BRG1 was measured in untreated and ADAADi-treated HeLa cells. In both these experiments, the percent ATPase activity was measure with respect to the untreated control at the respective time points.

Article Snippet: SMARCAL1 antibody was raised against N-terminus HARP domain by Merck (India) (Catalog # 106014).

Techniques: Expressing, Western Blot, Quantitation Assay, Software, Activity Assay, Control

Journal: PLoS ONE

Article Title: Global Epigenetic Changes Induced by SWI2/SNF2 Inhibitors Characterize Neomycin-Resistant Mammalian Cells

doi: 10.1371/journal.pone.0049822

Figure Lengend Snippet: (A). Comparing the in vivo ATPase activity of SMARCAL1 present in untransfected Neuro2A cells and stably transfected Neuro2A cells grown as indicated post-selection. (B). APH transcript expression in untransfected and transfected Neuro2A cells. (C). SWI2/SNF2 expression in untransfected and stably transfected Neuro2A cells grown as indicated was analysed using polyclonal anti-SMARCAL1 antibody, anti-Brg1 antibody, and anti- Rad54B antibody. (D). Western blot analysis of H3K9Ac levels in untransfected and stably transfected Neuro2A cells. (E). Western blot analysis of H3K9Me2 levels in untransfected and stably transfected Neuro2A cells grown as indicated by western blot. β-actin was used as loading control in these experiments. (F). The levels of ADH4, Nanog, Runx2, EP300, and Dicer1 was estimated by quantitative RT-PCR. The transcript levels in stably transfected cells were calculated with respect to the levels present in untransfected cells. The data are an average of two independent experiments, each experiment done in duplicate. Error bars indicate standard deviation and stars indicate statistical significance at P<0.05. The P-values are given in .

Article Snippet: The antibody against the HARP region of human SMARCAL1 was raised by Bangalore Genei (India).

Techniques: In Vivo, Activity Assay, Stable Transfection, Transfection, Selection, Expressing, Western Blot, Quantitative RT-PCR, Standard Deviation